Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 60

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 60
---
                                                  | 400.69 |     |                                        | 117.83 |     |               |   53 |
| 2020    |     |                                          |  5,685,664 |     |                                         | 12,015,409 |     |                                    | 5,363,707 |     |                                             | 10,455,559 |     |                                                  | 257.03 |     |                                        | 148.03 |     |               | -123 |

(1) Our Chief Executive Officer for each of the years presented was Dr. Rosen. Our Other NEOs for 2024, 2023 and 2022 were Robert C. Goeltz, Juan Jaen, Jennifer Jarrett and Dimitry Nuyten. Our Other NEOs for 2021 were Robert C. Goeltz, Juan Jaen, Jennifer Jarrett, Carolyn Tang and William Grossman. Our Other NEOs for 2020 were Jennifer Jarrett and William Grossman.

(2) Fair value or change in fair value, as applicable, of equity awards in the "compensation actually paid" columns was determined by reference to (i) for RSU awards, closing price on applicable year-end dates or, in the case of vesting dates, the actual vesting price and (ii) for stock options, the fair value estimated using a binomial lattice model as of the applicable year-end or vesting date(s). Key inputs included the contractual terms of each agreement such as vesting date, maturity date, and exercise price, while additional key inputs included the closing stock price, volatility, dividend rates, risk free rates, and an early-exercise factor which were all determined as of the revaluation date.

(3) The adjustments made to the summary compensation table total for Dr. Rosen for each year presented above to determine compensation actually paid to Dr. Rosen in such year are shown in the tables below:

|                                                                                                                   |     | 2024 |            |     | 2023 |            |     | 2022 |             |     | 2021 |            |     | 2020 |            |
| Summary compensation table total                                                                                  |     |      |  7,279,504 |     |      | 10,120,945 |     |      |   9,048,432 |     |      |  9,483,339 |     |      |  5,685,664 |
| Less, value of stock & option awards